Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 30

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 30
---
daq Capital Market (“Nasdaq”) under the symbol “RENB”. On October 29, 2024, the last reported sales price
for our common stock was $0.51 per share. The applicable prospectus supplement will contain information, where applicable, as to any other
listing of the securities on Nasdaq or any other securities market or exchange covered by the prospectus supplement. Prospective purchasers
of our securities are urged to obtain current information as to the market prices of our securities, where applicable.

We may offer the securities directly
or through agents or to or through underwriters or dealers. If any agents or underwriters are involved in the sale of the securities their
names, and any applicable purchase price, fee, commission or discount arrangement between or among them, will be set forth, or will be
calculable from the information set forth, in an accompanying prospectus supplement. We can sell the securities through agents, underwriters
or dealers only with delivery of a prospectus supplement describing the method and terms of the offering of such securities. See “Plan
of Distribution.”

The aggregate market value of
our outstanding common stock held by non-affiliates was approximately $111.9 million which was calculated based on 120,297,244 shares
of outstanding common stock held by non-affiliates as of October 16, 2024, and a price per share of $0.93, the closing price of our common
stock on October 16, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering
with a value of more than one-third of our public float in any 12-month period, so long as our public float is less than $75,000,000.
As of the date of this prospectus, we have not offered and sold any shares of our common stock pursuant to General Instruction I.B.6 to
Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.

Investing in our securities involves significant risks. We strongly recommend that you read carefully the risks we describe in this prospectus and in any accompanying prospectus supplement, as well as the risk factors that are incorporated by reference into this prospectus from our filings made with the Securities and Exchange Commission. See “Risk Factors” beginning on page 3 of this prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of